A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/55 (2006.01) A61K 31/00 (2006.01) A61K 31/135 (2006.01) A61K 31/275 (2006.01) A61K 31/44 (2006.01)
Patent
CA 2182114
The present invention comprises new methods for treating rheumatoid arthritis. It has been found that the L- type calcium channel antagonists are ef- fective in treating arthritis. Dihydropy- ridines, phenylalkylamines, and benzyl- diazepines are examples of the classes of L-type calcium channel antagonists en- compassed by the invention. Nimodip- ine, nisoldipine, nifedipine, verapamil and diltiazem are examples of specific compounds useful in the present inven- tion.
Nouvelles méthodes de traitemnt de l'arthrite rhumatoïde. On a trouvé que les antagonistes des vannes à calcium de type L sont efficaces pour traiter l'arthrite. Les dihydropyridines, les phénylalkylamines et les benzyldiazépines sont des exemples des classes d'antagonistes des vannes à calcium de type L entrant dans le cadre de la présente invention. La nimodipine, la nisoldipine, la nifédipine, le vérapamil et le diltiazem sont des composés spécifiques utiles dans la présente invention.
Borden Ladner Gervais Llp
Corporation Bayer
LandOfFree
Inhibition of arthritis by l-type calcium channel antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of arthritis by l-type calcium channel antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of arthritis by l-type calcium channel antagonists will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1462426